Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4283191
Max Phase: Preclinical
Molecular Formula: C26H31N5O3
Molecular Weight: 461.57
Molecule Type: Small molecule
Associated Items:
ID: ALA4283191
Max Phase: Preclinical
Molecular Formula: C26H31N5O3
Molecular Weight: 461.57
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: C=C(C)[C@@H]1CC=C(Cn2cc(COc3cccc(C4NC(=O)NC(C)=C4C(C)=O)c3)nn2)CC1
Standard InChI: InChI=1S/C26H31N5O3/c1-16(2)20-10-8-19(9-11-20)13-31-14-22(29-30-31)15-34-23-7-5-6-21(12-23)25-24(18(4)32)17(3)27-26(33)28-25/h5-8,12,14,20,25H,1,9-11,13,15H2,2-4H3,(H2,27,28,33)/t20-,25?/m1/s1
Standard InChI Key: RQMWGEKETHEORU-VGOKPJQXSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 461.57 | Molecular Weight (Monoisotopic): 461.2427 | AlogP: 4.38 | #Rotatable Bonds: 8 |
Polar Surface Area: 98.14 | Molecular Species: NEUTRAL | HBA: 6 | HBD: 2 |
#RO5 Violations: 0 | HBA (Lipinski): 8 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 12.53 | CX Basic pKa: | CX LogP: 2.99 | CX LogD: 2.99 |
Aromatic Rings: 2 | Heavy Atoms: 34 | QED Weighted: 0.57 | Np Likeness Score: -0.72 |
1. Vendrusculo V, de Souza VP, M Fontoura LA, M D'Oca MG, Banzato TP, Monteiro PA, Pilli RA, de Carvalho JE, Russowsky D.. (2018) Synthesis of novel perillyl-dihydropyrimidinone hybrids designed for antiproliferative activity., 9 (9): [PMID:30288229] [10.1039/C8MD00270C] |
Source(1):